16,741 Shares in Johnson & Johnson (NYSE:JNJ) Acquired by Berry Wealth Group LP

Berry Wealth Group LP purchased a new stake in Johnson & Johnson (NYSE:JNJ) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 16,741 shares of the company’s stock, valued at approximately $2,624,000. Johnson & Johnson accounts for approximately 2.4% of Berry Wealth Group LP’s portfolio, making the stock its 19th biggest position.

A number of other hedge funds also recently modified their holdings of the business. Global Wealth Management Investment Advisory Inc. lifted its holdings in Johnson & Johnson by 4.6% during the 4th quarter. Global Wealth Management Investment Advisory Inc. now owns 26,792 shares of the company’s stock worth $4,199,000 after buying an additional 1,179 shares during the period. Cary Street Partners Asset Management LLC increased its position in Johnson & Johnson by 3.1% during the 4th quarter. Cary Street Partners Asset Management LLC now owns 30,191 shares of the company’s stock valued at $4,732,000 after purchasing an additional 914 shares during the period. PYA Waltman Capital LLC lifted its position in shares of Johnson & Johnson by 4.8% in the 4th quarter. PYA Waltman Capital LLC now owns 34,909 shares of the company’s stock worth $5,472,000 after purchasing an additional 1,600 shares during the period. Hexagon Capital Partners LLC lifted its holdings in Johnson & Johnson by 24.5% in the fourth quarter. Hexagon Capital Partners LLC now owns 5,601 shares of the company’s stock valued at $878,000 after buying an additional 1,102 shares during the period. Finally, Thompson Davis & CO. Inc. raised its position in shares of Johnson & Johnson by 9.9% in the 4th quarter. Thompson Davis & CO. Inc. now owns 2,789 shares of the company’s stock worth $437,000 after acquiring an additional 251 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $149.27 on Monday. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.97. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.91 and a current ratio of 1.17. The firm’s 50-day simple moving average is $154.19 and its two-hundred day simple moving average is $155.03. The firm has a market cap of $359.25 billion, a price-to-earnings ratio of 9.31, a P/E/G ratio of 2.46 and a beta of 0.55.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The company had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. During the same period in the prior year, the company posted $2.68 EPS. Johnson & Johnson’s revenue was up 2.3% compared to the same quarter last year. As a group, equities analysts forecast that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.32%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date is Monday, May 20th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 29.68%.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Monday, April 15th. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and raised their target price for the company from $169.00 to $170.00 in a research note on Thursday, April 18th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Royal Bank of Canada lowered their price objective on shares of Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating on the stock in a report on Wednesday, April 17th. Finally, Morgan Stanley cut their price target on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 17th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $175.86.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.